Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Non-myeloablative hematopoietic stem cell transplantation.

M Maris1, B M Sandmaier, D G Maloney

  • 1Fred Hutchinson Cancer Research Center, Seattle, WA, United States.

Transfusion Clinique Et Biologique : Journal De La Societe Francaise De Transfusion Sanguine
|August 14, 2001
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Histone marks identify novel transcription factors that parse CAR-T subset-of-origin, clinical potential and expansion.

Nature communications·2024
Same author

Impact of patient: donor HLA disparity on reduced-intensity-conditioned allogeneic stem cell transplants from HLA mismatched unrelated donors for AML: from the ALWP of the EBMT.

Bone marrow transplantation·2020
Same author

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

Leukemia·2020
Same author

Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic stem cell transplantation program in countries with limited resources (Part II): Clinical, technical and socio-economic considerations.

Hematology/oncology and stem cell therapy·2019
Same author

Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysis.

Journal of internal medicine·2018
Same author

An algorithm for suboptimally placed supraglottic airway devices: the choice of videolaryngoscope.

British journal of anaesthesia·2017

Reduced-intensity conditioning for stem cell transplantation shows promise for improved safety. This approach may expand access to potentially curative hematopoietic stem cell transplantation (HSCT) for more patients.

Area of Science:

  • Hematology
  • Immunology
  • Transplantation Medicine

Background:

  • Conventional allogeneic stem cell transplantation relies on high-dose conditioning therapy, associated with significant toxicities.
  • Preclinical and clinical data suggest that reduced-intensity conditioning can achieve engraftment with lower toxicity.
  • Potent immunosuppression is key to facilitating stable mixed hematopoietic chimerism.

Purpose of the Study:

  • To evaluate the safety and efficacy of attenuated conditioning regimens in hematopoietic stem cell transplantation (HSCT).
  • To explore the potential of HSCT with reduced toxicity for a broader patient population, including older and sicker individuals.
  • To investigate the role of mixed hematopoietic chimerism in treating nonmalignant hematologic and immune disorders.

Main Methods:

Related Experiment Videos

  • Utilizing potent pre- and postgrafting immunosuppression in a preclinical canine model.
  • Applying attenuated conditioning regimens in initial clinical experiences.
  • Observing graft-versus-host (GVH) reactions in patients with hematopoietic malignancy.

Main Results:

  • Stable mixed hematopoietic chimerism was achieved in a preclinical canine model.
  • Initial clinical experiences with attenuated conditioning regimens demonstrate an improved safety profile for HSCT.
  • Mixed hematopoietic chimerism shows potential for curing nonmalignant hematologic and immune disorders.

Conclusions:

  • Reduced-intensity conditioning offers a safer alternative for hematopoietic stem cell transplantation (HSCT).
  • This approach could broaden eligibility for HSCT, benefiting older and medically compromised patients.
  • While promising for nonmalignant conditions, managing graft-versus-host reactions remains crucial for treating hematopoietic malignancies.